Genmab's petosemtamab shows durable clinical activity in metastatic colorectal cancer, with 81% response rates in specific patient subgroups, bolstering the firm's Phase 3 clinical strategy.
Genmab's updated Phase 2 data for petosemtamab in metastatic colorectal cancer (mCRC) demonstrates strong clinical efficacy, with objective response rates (ORR) of 75% in first-line and 67% in second-line settings. These results, presented at ESMO 2026, validate the drug's unique triple mechanism of action and provide a robust foundation for the company's ongoing global Phase 3 LiGeR development program. The durability of these responses, particularly in difficult-to-treat subgroups like patients with liver metastases, significantly strengthens the investment case for Genmab's oncology pipelin
It is a bispecific antibody targeting EGFR and LGR5, designed to inhibit EGFR signaling, trigger EGFR degradation in cancer stem-like cells, and enhance immune-mediated activity.
The trial showed a 75% ORR in first-line patients and 67% in second-line patients, with an 81% ORR in first-line patients with left-sided tumors.
Genmab A/S announced positive updated Phase 2 results for its investigational antibody, petosemtamab, in patients with metastatic colorectal cancer. The study demonstrated objective response rates of 75% in first-line and 67% in second-line settings, supporting the company's ongoing global Phase 3 development program.
Petosemtamab is a bispecific antibody that targets both EGFR and LGR5, inhibiting EGFR signaling while triggering degradation of cancer stem-like cells.